# Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

Source: https://onco.cc/trials/nct07504263/  
OnCo record `nct07504263` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by Recurv Pharma Inc, not yet recruiting.

## Summary

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies is a phase 1/2, interventional study registered as NCT07504263 by Recurv Pharma Inc, with a registry enrolment figure of 66 participants, started 2026-04-23 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP-001. Conditions listed: Advanced Malignancies; Oncology; Colorectal Cancer; Pancreatic Cancer; Cancer. Primary outcome: To characterize the safety and tolerability of RP-001 administered as monotherapy.. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07504263
- Phase: 1/2
- Setting: An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies
- Sponsor: Recurv Pharma Inc
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT07504263: https://clinicaltrials.gov/study/NCT07504263

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07504263.json